lumevarin · Neurology · CGRP receptor antagonist for preventive treatment of episodic migraine.
3 objectives · 2 on track, 1 at risk
| Objective | Product | Owner | Status | Progress | Confidence |
|---|---|---|---|---|---|
| SO-LMV-01Publish real-world persistence and switching evidence across three markets. | Lumeva | EMDr. Elena Moretti | On track | 80% | High |
| SO-LMV-02Support the chronic-migraine lifecycle extension with a scientific platform and pre-submission KOL alignment. | Lumeva | EMDr. Elena Moretti | On track | 57% | Medium |
| SO-LMV-03Reduce medical-information response time for dosing and interaction queries to a median of 2 business days. | Lumeva | FAFatima Al-Sayed | At risk | 45% | Medium |
Initiative status mix per product; mean initiative progress alongside.
Periodic review
3 initiatives · 62% mean progress
Status order: Completed · In progress · Planned · Not started · At risk · Blocked. Colours follow the status label shown in each legend.
Top 8 topics by insight count (duplicates excluded). Trend compares the last 60 days with the prior 60 days.
| Theme | Insights | Mean priority | Critical / High | Open high-priority | Trend (60d) |
|---|---|---|---|---|---|
| Switching between CGRP agents | 6 | 65 | 33% | 2 | Rising 2 vs 1 |
| Drug interactions | 5 | 63 | 60% | 1 | Flat 1 vs 1 |
| Chronic migraine data | 5 | 57 | 40% | 1 | Falling 1 vs 3 |
| Dosing in hepatic impairment | 2 | 69 | 100% | 2 | Rising 2 vs 0 |
| Medication-overuse headache | 2 | 61 | 50% | 1 | Rising 1 vs 0 |
| Real-world persistence | 2 | 60 | 50% | 0 | Falling 0 vs 1 |
1 initiatives at risk or blocked · 0 overdue tasks and actions
| Type | Item | Owner | Due | Status | Linked record |
|---|---|---|---|---|---|
| Initiative | INI-0303Lumeva MI dosing/interaction standard-response refresh | FAFatima Al-Sayed | 31 Oct 2026 (in 46 days) | At risk | Objective · SO-LMV-03 |
Submitted and reviewed engagements, FY2026 to date.
By stakeholder tier
Mean quality rating (1–5)
Mean 3.3 across 62 rated engagements: 1★ 0 · 2★ 6 · 3★ 28 · 4★ 26 · 5★ 2
Unique stakeholders
33
62 engagements
Tier 1 covered (6 mo)
11 / 16
69%
In person / virtual / phone
33 / 17 / 12
27% virtual
With ≥ 1 insight
23
37%
SLA compliance (MET-041) · target 92% · monthly, global scope
Jan 93.1% · Feb 92.4% · Mar 91.8% · Apr 92% · May 91.2% · Jun 90.6% · Jul 89.9% · Aug 89.4% · Sep 90.2%
The trend line is global; the counts below follow the selected scope.
Inquiries YTD
245
Open
2
Overdue
1
Breached (closed)
53
Escalated / safety
2 / 3
2 active publications · 2 of 2 planned submissions to date are submitted or beyond
Delayed milestones (0)
No publication milestones are past due.
3 projects · 1 active · 0 active at high risk
Feasibility review 1 · Data collection 1 · Publication 1
By evidence gap
| Evidence gap | Projects | Active | Budget |
|---|---|---|---|
| Real-world persistence and switching patterns | 1 | 0 | $310k |
| Long-term hepatic safety | 1 | 1 | $1.8M |
| Outcomes in patients with medication-overuse headache | 1 | 0 | $220k |
Weighted completion across scorecard dimensions. Grey dimensions carry no score; stale dimensions were last reviewed more than 30 days ago.
No launch scorecard for this product
Scorecards exist for products in launch or pre-launch.
FY2026 · planned $3.6M · committed $3.5M · actual $2.8M (79% consumed) · 1 line at overrun risk
| Product | Planned | Committed | Actual | Consumed | Lines at risk |
|---|---|---|---|---|---|
| Lumeva | $3.6M | $3.5M | $2.8M | 79% | BL-023 (Research) |
4 teams · 3 over-allocated
Over-allocated teams
0 decisions proposed or under review
No decisions are awaiting leadership in this scope.
Tenant-wide; not narrowed by product or region.
Open DQ issues
14
3 high · 7 medium · 4 low
Integrations degraded / failed
2
Veeva CRM (Degraded), Veeva Vault CTMS (Failed)
AI outputs pending review
3
INS-0061, INS-0060, RPT-Q3-EXEC
Metrics with DQ warnings
0
None
helixor-private-llm-2026.08 · generated 2026-09-15 06:00 UTC · scope: Lumeva · All regions · unapproved narratives are never distributed
Human review required
Strategic objectives
2 of 3 objectives are on track; 1 is at risk or off track (SO-LMV-03). Mean progress is 61% against a 70% year-end target.
Initiatives at risk
1 initiative is at risk or blocked: Lumeva MI dosing/interaction standard-response refresh (at risk).
Sources:INI-0303
Escalated risks
No risks are currently escalated.
Sources:none — derived from portfolio counts
Insights needing action
All Critical and High insights have been routed.
Sources:none — derived from portfolio counts
Publication milestones
No publication milestones are past due.
Sources:none — derived from portfolio counts
Decisions needed
No decisions are awaiting leadership.
Sources:none — derived from portfolio counts